Keywords: boron neutron capture therapy; brainstem tumor; diffuse midline glioma; compassionate
use; bevacizumab

Keywords: BNCT, clinical boron neutron capture therapy, Japan

Keywords: BNCT; BPA; linear accelerator; radiation therapy; Korea

Keywords: BNCT; neutron capture; particle therapy; neutron therapy; boron

Keywords: boron neutron capture therapy, BNCT, accelerator-based BNCT system

Keywords: Boron neutron capture therapy, Boron carriers, Neutron source, Tumor

Keywords: particle beam therapy; proton beam therapy; carbon-ion beam therapy; boron neutron capture therapy; combination therapy; drug delivery

Keywords: boron neutron capture therapy (BNCT); boron-containing nanoparticles; magnetic resonance imaging (MRI)

Keywords: BNCT; 18FBPA; PET

Keywords: radiobiology; BNCT; BPA; melanoma; clinical outcome

The results of this study provide a reference for other clinicians or radiation oncologists conducting BNCT treatment for such patients.

Accelerator-driven neutron sources have been developed worldwide for boron neutron capture therapy (BNCT) instead of nuclear reactors.

Background and purpose: Boron neutron capture therapy (BNCT) can be performed without reactors due to development of cyclotron-based epithermal neutron source (C-BENS), which is optimized for treatment for deeper-seated tumors.

As glioma stem cells are chemo- and radio-resistant, they could be the origins of recurrent malignant glioma. Boron neutron capture therapy (BNCT) is a tumor-selective particle radiation therapy. ¹⁰B(n,α)⁷Li capture reaction produces alpha particles whose short paths (5–9 µm) lead to selective killing of tumor cells.

A 52-year-old woman was diagnosed with leftparietalglioblastoma, and underwent craniotomy with near total tumor removal on October 11th, 2017.

Our aim was to assess the long-term clinical outcome of boron neutron capture therapy (BNCT) using ¹⁰B-paraboronophenylalanine (BPA) as the boron delivery agent for cutaneous melanoma.

A 39-year-old man had received boron neutron capture therapy (BNCT) for a grade II astrocytoma (compatible with diffuse astrocytoma, not otherwise specified in the WHO 2016 criteria).

Existing and active low-energy Accelerator-Based BNCT programs worldwide will be reviewed and compared.